Tag Archives: Blincyto

April, 2018

March, 2017

  • 30 March

    FDA Grants Priority Review to Amgen’s Blincyto sBLA

    THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study. The application also includes new …

September, 2016

July, 2016

  • 27 July

    Cytokinetics and Astellas Expand Collaboration into ALS

    SOUTH SAN FRANCISCO, Calif. and TOKYO, July 27, 2016 (GLOBE NEWSWIRE) — Cytokinetics, Inc.(Nasdaq:CYTK) (“Cytokinetics”) and Astellas Pharma Inc. (TSE:4503) (“Astellas”) today announced that Cytokinetics and Astellas have expanded their collaboration in skeletal muscle activators to include amyotrophic lateral sclerosis (ALS).  Through this expansion, Cytokinetics has granted Astellas an option …

June, 2016

May, 2016

February, 2016

  • 5 February

    Amgen’s Blincyto Meets Primary Endpoint in Late-Stage ALL Study

    THOUSAND OAKS, Calif., Feb. 4, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO® (blinatumomab) versus standard of care …

December, 2015

  • 4 December

    Amgen and Merck Enter Cancer Immunotherapy Collaboration for NHL

    THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large …